A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

This trial tests a new combination of two experimental drugs — AK130 and AK112 — in people with advanced pancreatic cancer that has spread and progressed after previous treatments. AK112 is an immunotherapy drug and AK130 blocks a protein that helps tumors grow. **You may be eligible if...** - You have been diagnosed with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) - Your cancer progressed after 1 or 2 prior lines of treatment - You are generally well enough for treatment (ECOG performance score 0–1) - You have a life expectancy of at least 3 months - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have been diagnosed with another cancer in the last 5 years - Your cancer has spread to the brain or spinal cord - You have significant fluid buildup around your lungs, heart, or abdomen - You have previously been treated with TGF-β inhibitors or anti-angiogenic drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.